Using M2 Macrophages to Treat Periodontitis
Treatment of Periodontitis by Homing M2 Macrophages
This study is testing a new way to help people with gum disease by using special immune cells to reduce inflammation and protect against bone loss, making it a potentially better option than the usual treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10893996 on NIH RePORTER |
What this research studies
This research investigates a new treatment for periodontitis, a common inflammatory disease affecting the gums and teeth. The approach focuses on using M2 macrophages, a type of immune cell, to reduce inflammation and prevent bone loss associated with the disease. By injecting specific microparticles that release a signaling molecule (CCL2) into the affected areas, the study aims to enhance the body's natural healing response. This innovative method could provide a more effective solution compared to current treatments that primarily target bacterial infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults suffering from periodontitis, particularly those who have not responded well to standard treatments.
Not a fit: Patients with mild gum disease or those who do not have periodontitis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel therapy that not only treats periodontitis but also prevents related systemic diseases.
How similar studies have performed: Previous studies have shown promising results in using M2 macrophages for treating inflammatory conditions, indicating potential for success in this novel application.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Sfeir, Charles — University of Pittsburgh at Pittsburgh
- Study coordinator: Sfeir, Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.